Search

10X Genomics Inc (Class A)

Lezárt

SzektorEgészségügy

56.03 -3.15

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

55.69

Maximum

56.99

Fő mutatók

By Trading Economics

Bevétel

-4.5M

-18M

Értékesítés

193K

151M

Egy részvényre jutó nyereség

-0.14

Profit margin

-11.872

Munkavállalók

1,178

EBITDA

-18M

-19M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

-12.16% downside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.7B

7.6B

Előző nyitás

59.18

Előző zárás

56.03

Hangulat hírek alapján

By Acuity

100%

0%

329 / 340 Rangsor szerint Healthcare

10X Genomics Inc (Class A) Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 14. 20:06 UTC

10X Genomics Inc shares are lower today amid mixed market sentiment following a reported decline in U.S. retail sales for July.

2026. aug. 13. 19:16 UTC

News

10X Genomics Inc reported Q2 revenue of $151 million, exceeding estimates. Shares are higher as management raises full-year revenue guidance to $620 million.

2026. aug. 12. 19:46 UTC

10X Genomics Inc. shares are lower today, having retraced from an early peak. The stock remains above its 20-day moving average.

2026. aug. 11. 20:06 UTC

10X Genomics Inc. shares are lower today amid routine trading, despite earlier fluctuations and remaining above the 20-day moving average.

2026. aug. 10. 20:03 UTC

News
Social Media
Correlated Moves

10X Genomics shares rise as Piper Sandler and Canaccord Genuity raise price targets to $47.00 and $60.00, respectively, amid increased trading volume.

2026. aug. 7. 23:16 UTC

News

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

2026. aug. 6. 23:02 UTC

News

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

2026. aug. 5. 19:26 UTC

Correlated Moves
News

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

2026. aug. 3. 19:36 UTC

Correlated Moves
Social Media

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

2026. júl. 31. 19:36 UTC

Correlated Moves
Social Media

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

2026. júl. 30. 17:06 UTC

Correlated Moves

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

2026. júl. 29. 19:27 UTC

Macro Event
News

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

2026. júl. 28. 23:11 UTC

10X Genomics Inc. is trading higher in after-market hours, maintaining a position near its one-month range's upper end. No specific news was identified for the move.

2026. júl. 27. 18:36 UTC

10X Genomics Inc shares are lower today, with no specific news identified. The stock remains near the upper end of its one-month range.

2026. júl. 24. 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

2026. júl. 23. 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

2026. júl. 22. 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

2026. júl. 21. 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

2026. júl. 20. 19:16 UTC

News
Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Társak összehasonlítása

Árváltozás

10X Genomics Inc (Class A) Előrejelzés

Célár

By TipRanks

-12.16% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 49.27 USD  -12.16%

Magas 65 USD

Alacsony 40 USD

13 Wall Street elemző 12 hónapos célárain alapulva a(z)10X Genomics Inc (Class A) termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

13 ratings

6

Vétel

7

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat